NFL Biosciences SA (EPA:ALNFL)

Market Cap	16.25M -11.7%
Revenue (ttm)	164.00 +320.5%
Net Income	-3.15M
EPS	n/a
Shares Out	12.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	414,271
Average Volume	188,271
Open	1.202
Previous Close	1.282
Day's Range	1.172 - 1.316
52-Week Range	0.851 - 2.100
Beta	1.31
RSI	44.95
Earnings Date	Apr 2, 2026

About NFL Biosciences

NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company’s pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 5
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALNFL

Financial Performance

In 2024, NFL Biosciences's revenue was 46, a decrease of -99.98% compared to the previous year's 200,011. Losses were -2.08 million, -44.44% less than in 2023.